» Articles » PMID: 38558655

Beneath the Surface: Exploring Hidden Threats of Long-Term Corticosteroid Therapy to Bone Density

Abstract

Within the field of medical treatments, corticosteroids are potent substances that efficiently reduce inflammation and immunological responses, making them essential for the management of a wide range of medical ailments. However, continued use of these synthetic drugs presents a serious risk: the onset of osteoporosis brought on by corticosteroids. Determining the complex pathways by which corticosteroids cause a general disturbance in bone metabolism, suppress osteoblast function, increase osteoclast activity, and upset the delicate balance of bone remodelling emphasizes the need for all-encompassing management and prevention approaches. In this review, we aim to expose the complexities of corticosteroid-induced bone loss and urge for personalized, proactive measures to improve long-term therapeutic outcomes.

References
1.
Angeli A, Dovio A, Sartori M, Masera R, Ceoloni B, Prolo P . Interactions between glucocorticoids and cytokines in the bone microenvironment. Ann N Y Acad Sci. 2002; 966:97-107. DOI: 10.1111/j.1749-6632.2002.tb04207.x. View

2.
Haseltine K, Chukir T, Smith P, Jacob J, Bilezikian J, Farooki A . Bone Mineral Density: Clinical Relevance and Quantitative Assessment. J Nucl Med. 2020; 62(4):446-454. PMC: 8049374. DOI: 10.2967/jnumed.120.256180. View

3.
Berger A . Bone mineral density scans. BMJ. 2002; 325(7362):484. PMC: 1124002. DOI: 10.1136/bmj.325.7362.484. View

4.
LeBoff M, Greenspan S, Insogna K, Lewiecki E, Saag K, Singer A . The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022; 33(10):2049-2102. PMC: 9546973. DOI: 10.1007/s00198-021-05900-y. View

5.
Chmielnicka M, Wozniacka A, Torzecka J . The influence of corticosteroid treatment on the OPG/RANK/RANKL pathway and osteocalcin in patients with pemphigus. Postepy Dermatol Alergol. 2014; 31(5):281-8. PMC: 4221354. DOI: 10.5114/pdia.2014.44016. View